Navigation Links
WorldHeart Notified of TSX Delisting Review
Date:5/12/2008

OAKLAND, Calif., May 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) World Heart Corporation ("WorldHeart" or the "Corporation") announced that the Toronto Stock Exchange ("TSX") issued a Bulletin today advising it is reviewing the eligibility for continued listing on the TSX of the common shares of WorldHeart under sections 709 and 710(a) of the TSX Company Manual. This review relates to the Company's financial condition and operating results, more specifically whether the Company can continue as a going concern. Further to the TSX's Remedial Review Process, WorldHeart has been granted 30 days in which to demonstrate compliance with these requirements. The Company is also permitted to make submissions regarding this matter at a hearing scheduled to be held on June 5, 2008. If the Company cannot demonstrate that it meets all TSX requirements on or before June 11, 2008, the Company's common shares will be delisted 30 days from such date.

The notice also states that if at anytime, TSX becomes aware of additional negative developments such that the continued trading or listing of a Company's securities is contrary to public interest, an expedited review will be initiated.

On the same day, WorldHeart received a notice from the TSX that the Company improperly disseminated material information by failing to issue a news release immediately. The news release was circulated on May 9, 2008, when it should have been circulated on May 8, 2008 at the same time the Company filed its public disclosure with the US and Canadian securities commissions. The Company's management has made policy changes to ensure timely disclosure of material events, as required under section 4(b) of the TSX Company Manual.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB for the year ended December 31, 2007.


'/>"/>
SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Vion Pharmaceuticals to Appeal Nasdaq Delisting
3. QMed, Inc. Receives NASDAQ Delisting Letter
4. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
5. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
6. Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response
7. Review of cervical cancer screening program shows effectiveness and room for improvement
8. Systematic Review of Patient-Reported Outcomes (PROs) Can Reduce Cost of Cancer Care
9. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
10. Review Urges Aggressive MRSA Screening for Health Workers
11. ACC Calls on FDA to Update Review of Bisphenol A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated ... Institute. For Betsy, the clinical trial has been life-saving as she has been ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and ... out for each of his children. “The Angel” is the creation of published author, ... New York City, and impassioned writer. , When asked of her new book, Marjorie ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas in ... where she works in a daycare and looks for inspiration in the local coffee ... Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology: